Ligand Pharmaceuticals stock hits 52-week high at $169.72

Published 18/09/2025, 17:24
Ligand Pharmaceuticals stock hits 52-week high at $169.72

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has reached a new 52-week high, with its stock price climbing to $169.72. According to InvestingPro data, the stock is currently trading above its Fair Value, with analysts setting price targets between $164 and $206. This milestone reflects a significant uptick in investor confidence and market performance. Over the past year, Ligand Pharmaceuticals has experienced a remarkable 61.18% increase in its stock value, with particularly strong momentum shown in its 55.7% gain over the past six months. The company maintains a healthy financial position with a current ratio of 5.45, though InvestingPro analysis indicates the stock may be in overbought territory. The company’s ability to achieve this 52-week high indicates positive momentum, aligning with broader market trends and investor sentiment within the biotechnology sector. For deeper insights, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro, covering this and 1,400+ other top US stocks.

In other recent news, Ligand Pharmaceuticals has been at the center of several notable developments. The company reported strong second-quarter 2025 earnings, prompting Benchmark to raise its price target for Ligand Pharma to $175, maintaining a Buy rating. In a similar move, Oppenheimer increased its price target to $190, citing a mid-August capital raise that generated approximately $385 million through a $460 million convertible debt offering. H.C. Wainwright also raised its price target to $206 following the FDA’s approval of an update to the REMS labeling for FILSPARI, which included reduced liver function monitoring requirements.

Ligand Pharmaceuticals completed its $460 million convertible notes offering, which included the full exercise of the initial purchasers’ option to buy an additional $60 million in notes. The company reported net proceeds of approximately $445.1 million after fees and expenses. Prior to this, Ligand had priced $400 million of 0.75% convertible senior notes due 2030 in a private placement to qualified institutional buyers. These recent financial activities and regulatory updates have contributed to the analysts’ optimistic outlooks.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.